CTRI/2025/06/089678尚未招募1 期
Therapeutic impact of resveratrol on healing and inflammation following mandibular third molar extraction - a randomized controlled study
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- CTRI
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Swelling measured by linear facial measurements on Day 1, Day 3, and Day 7.
研究概览
简要总结
This will be a randomized, double-blind, placebo-controlled, parallel-group clinical trial conducted to evaluate the role of Resveratrol in accelerating postoperative recovery following the surgical extraction of impacted mandibular third molars.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Double Blind Double Dummy
入排标准
- 年龄范围
- 18.00 Year(s) 至 45.00 Year(s)（—）
- 性别
- All
入选标准
- •Inclusion Criteria: 1.Patients aged between 18 and 40 years.
- •2.Indicated for surgical extraction of a single impacted mandibular third molar (mesioangular, horizontal, or vertical impaction).
- •3.Systemically healthy individuals (ASA I or II).
- •4.Patients willing to participate and able to provide written informed consent.
- •5.Patients with no history of allergy to Resveratrol or any components of the formulation used.
- •6.Patients available for follow-up and compliant with postoperative instructions.
排除标准
- •Exclusion Criteria: 1.Patients with systemic conditions that may affect healing (e.g., diabetes mellitus, immunocompromised states).
- •2.Current or recent use (within the past 2 weeks) of anti-inflammatory, antioxidant, or immunosuppressive medications.
- •3.History of hypersensitivity or allergy to Resveratrol or related compounds.
- •4.Pregnant or lactating women.
- •5.Active infection or pathology at the surgical site.
- •6.History of alcohol or substance abuse.
- •7.Patients with poor oral hygiene or active periodontal disease near the surgical sites 8.Smoking or tobacco use in any form.
- •9.Participation in another clinical trial within the last 30 days.
结局指标
主要结局
Swelling measured by linear facial measurements on Day 1, Day 3, and Day 7.
时间窗: 7 days
Pain reduction assessed by Visual Analog Scale (VAS) on postoperative Day 1, Day 3, and Day 7.
时间窗: 7 days
Trismus assessed by maximum interincisal mouth opening on Day 1, Day 3, and Day 7.
时间窗: 7 days
次要结局
- Secondary Outcomes:(Quality of wound healing assessed clinically using a standard wound healing index on Day 7.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Clinical trial of Re-Cart capsules in knee osteoarthritisCTRI/2023/02/049625Cachet Pharmaceuticals Pvt.Ltd50
Enrolling By Invitation
不适用
Effect of Increasing Total Antioxidant Capacity in Autism Spectrum DisorderAutism Spectrum DisorderNCT06623227Rinvil Renaldi50
终止
3 期
An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.Acute Pain From Ankle Sprain or StrainNCT02089425Kowa Research Institute, Inc.384
已完成
3 期
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyNon-Small Cell Lung CancerNCT01364012Hoffmann-La Roche276
已完成
2 期
A clinical trial to study the safety and effectiveness of ME-015 (Suplatast Tosilate) in cough related to Idiopathic Pulmonary Fibrosis disease, a disease that causes scarring (fibrosis) of the lungsCTRI/2024/01/061637Syngene International Limited40